For research and educational purposes only. Not intended for human consumption.
PT-141
Extensively Studied- •Phase 2 trial with PDE5 inhibitor co-administration (2024)
- •FDA-approved for HSDD treatment
- •New intranasal formulation studies
Bremelanotide | Melanocortin Receptor Agonist
Overview
What is PT-141?
PT-141 (Bremelanotide) is an FDA-approved synthetic peptide that acts as a melanocortin receptor agonist, specifically targeting MC3R and MC4R receptors in the central nervous system. Unlike traditional ED medications that work through vascular mechanisms, PT-141 directly influences sexual arousal pathways in the brain through dopamine release, making it effective for both male and female sexual dysfunction. A Phase 2 clinical trial (2024) is evaluating bremelanotide co-administered with PDE5 inhibitors for ED treatment in non-responders.
Key Benefits
FDA-approved route with predictable absorption, works within 45 minutes, effective for both male and female sexual dysfunction. Brain-focused mechanism differentiates it from PDE5 inhibitors, showing promise for psychological or central components of sexual dysfunction.
Mechanism of Action
Binds to melanocortin receptors (MC3R/MC4R) in the hypothalamus, mimicking α-MSH to trigger dopamine release, enhancing sexual arousal, desire, and erectile signals via central nervous system pathways rather than direct vascular effects. Effects start ~30-60 minutes post-subcutaneous injection.
Molecular Information
Pharmacokinetics
Research Indications
Hypoactive Sexual Desire Disorder (HSDD)
FDA-approved for premenopausal women with acquired, generalized HSDD.
Erectile Dysfunction
Effective in men including those unresponsive to PDE5 inhibitors.
Female Sexual Arousal Disorder
Improves physiological and subjective arousal measures.
Research Protocols
Disclaimer: PT-141 is FDA-approved (as Vyleesi) for HSDD in premenopausal women. These protocols are for research purposes. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Female HSDD (FDA-approved) | 1.75mg | As needed, max 1 dose/24hr | Subcutaneous |
| Male Erectile Dysfunction | 1-2mg | As needed, 45-60min before activity | Subcutaneous |
| Female Arousal Disorder | 0.75-1.25mg | As needed, max 1 dose/24hr | Subcutaneous |
| Low Starting Dose | 0.5mg | Test dose to assess tolerance | Subcutaneous |
Timing: Best taken 45-60 minutes before sexual activity. Can be taken with or without food, though food may reduce nausea. Effects last 6-12 hours.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Allow vial to reach room temperature (15-20 minutes)
Clean vial tops with alcohol swabs
Draw 1-2mL bacteriostatic water (1mL for higher concentration)
Inject BAC water slowly down the side of PT-141 vial
Gently swirl (do not shake) until fully dissolved
Solution should be clear and colorless
Store reconstituted solution in refrigerator
Use within 30 days of reconstitution
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
FDA-Approved Pharmaceutical Grade
If prescribed as Vyleesi, guaranteed pharmaceutical quality and safety.
White Crystalline Powder
Pure PT-141 appears as white to off-white lyophilized powder.
Clear Solution When Reconstituted
Properly manufactured PT-141 dissolves completely without cloudiness.
Colored or Oily Appearance
May indicate impurities or degradation - do not use.
Compounded Versions
Ensure compounding pharmacy is licensed and follows USP standards.
What to Expect
- •First 30-45 minutes: May experience mild nausea or facial flushing
- •45-90 minutes: Onset of effects - increased arousal and desire
- •2-4 hours: Peak effects - enhanced sexual response
- •6-12 hours: Effects gradually diminish
- •Long-term: No tolerance development reported with intermittent use
Side Effects & Safety
Side Effects
- •Common side effects: nausea (40%), flushing (20%), headache (11%)
- •Take anti-nausea medication 30 minutes before if prone to nausea
- •Monitor blood pressure - can cause transient decrease
- •Not for use with uncontrolled hypertension or cardiovascular disease
- •Avoid alcohol to minimize blood pressure effects
- •FDA black box warning for blood pressure effects
When to Stop
- •Severe or persistent nausea/vomiting
- •Significant blood pressure changes
- •Allergic reactions
- •Chest pain or shortness of breath
- •Consult healthcare provider immediately
References
4 StudiesPhase 2 Trial: Bremelanotide + PDE5i (2024)
Human | ~50 men | Open-label dose-escalation | PDE5i non-responders (30-40% of ED patients)
FDA-cleared Phase 2 trial evaluating subcutaneous bremelanotide co-administered with PDE5 inhibitors in men who don't respond to traditional ED medications. Topline results expected end of 2024, with potential Phase 3 in early 2025 - the first new class in ~20 years.
FDA Approval Trial for HSDD
Human | 1.75mg subcutaneous | As needed | 24.5% improvement vs 17.2% placebo
Phase 3 trials in premenopausal women with HSDD showed statistically significant improvements in sexual desire and reduced distress, leading to FDA approval as Vyleesi.
Male Erectile Dysfunction Double-Blind Trial
Human | Bremelanotide vs placebo | NCT01382719 | Statistically significant ED improvements
Double-blind clinical study reported statistically significant erectile function improvements versus placebo, supporting efficacy in male sexual dysfunction.
Quick Start Guide
Research Disclaimer
PT-141 is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving PT-141 must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of PT-141 for any purpose. Consult qualified professionals for any research applications.